Transient plasticity response is regulated by histone deacetylase inhibitor in oxygen–glucose deprivation condition

Chu, Ming-Chia; Mao, Wei-Chang; Wu, Han-Fang; Chang, Yun-Chi; Lu, Ting-I; Lee, Chi-Wei; Chung, Yueh-Jung; Hsieh, Tsung-Han; Chang, Hsun-Shuo; Chen, Yih-Fung; Lin, Chia-Hsien; Tang, Chih-Wei; Lin, Hui-Ching

doi:10.1007/s43440-023-00525-w

Cited by 1 publication

(1 citation statement)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3 Current therapeutic strategies for ischaemic stroke include thrombolytic therapy administrated within the critical 4.5 hours time window following the onset of ischaemia. 4 Nonetheless, only a limited number of individuals suffering from acute ischaemic stroke receive treatment with tissue plasminogen activators, due to the limited time window. Consequently, there is an increasing need to provide alternative or complementary options for the management of these patients.…”

Section: Introductionmentioning

confidence: 99%

Role of histone deacetylases and sirtuins in the ischaemic stroke: a protocol for a systematic review and meta-analysis of animal studies

Majdi,

Mostafavi,

Moharrami

et al. 2024

Stroke Vasc Neurol

View full text Add to dashboard Cite

BackgroundStroke is a major cause of global mortality and disability. Currently, the treatment of acute ischaemic stroke through reperfusion has posed several challenges, raising the need for complementary options to protect the ischaemic penumbra. Recent investigations have indicated that certain epigenetic factors, specifically, histone deacetylases (HDACs) and sirtuins, can be promising for ischaemic stroke therapy, with recent studies suggesting that inhibitors of HDACs or sirtuins may provide neuronal protection after ischaemic stroke. However, the impact of specific HDAC/sirtuin isoforms on the survival of neuronal cells following stroke is still uncertain. This study aims to provide a comprehensive overview of the function of HDACs and their modulators in the treatment of acute ischaemic stroke.MethodsThis systematic review and meta-analysis will encompass animal intervention studies that explore the efficacy of modulation of HDACs and sirtuins in the acute phase of ischaemic stroke. The review will be reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Electronic searches will be conducted in PubMed, Web of Science and Scopus, with subsequent screening by independent reviewers based on the established eligibility criteria. Methodological quality will be evaluated using the SYRCLE risk of bias tool. The primary outcomes will be infarct volume and functional response, with the secondary outcomes established a priori. Data pertaining to infarct volume will be used for random-effects meta-analysis. Additionally, a descriptive summary will be conducted for the functional response and secondary outcomes.DiscussionNo systematic review and meta-analysis on the treatment of ischaemic stroke through HDAC modulation has been conducted to date. A comprehensive analysis of the available literature on the relevant preclinical investigations can yield invaluable insights in discerning the most effective trials and in further standardisation of preclinical studies.Systematic review registrationThis systematic review has been recorded in the International Prospective Register of Systematic Reviews (PROSPERO), with the assigned reference number: CRD42023381420

show abstract

Section: Introductionmentioning

confidence: 99%